Summary Flavone acetic acid (FAA) is a novel antitumour agent that has a profound effect on the vasculature in murine tumour models. Previously we have shown that FAA induces a coagulopathy and thrombocytopaenia in tumour-bearing mice, and the purpose of the present study was to determine the significance of the FAA-induced intravascular coagulation in the antitumour action of FAA. Several anticoagulant agents were tested for their effectiveness in altering ex vivo coagulation of murine plasma; heparin and ancrod were found to be most effective. These agents were administered to tumour-bearing mice prior to FAA and TNF treatment with little effect on the induced regrowth delay. However: the FAA-induced consumption of platelets in tumour-bearing mice was not blocked by anticoagulant treatment. These data suggest that platelet consumption occurs independently of the normal coagulation pathway, and further that fibrin deposition may not be a major factor in the antitumour action of FAA.
Summary Flavone acetic acid (FAA) is a novel antitumour agent that has a profound effect on the vasculature in murine tumour models. Previously we have shown that FAA induces a coagulopathy and thrombocytopaenia in tumour-bearing mice, and the purpose of the present study was to determine the significance of the FAA-induced intravascular coagulation in the antitumour action of FAA. Several anticoagulant agents were tested for their effectiveness in altering ex vivo coagulation of murine plasma; heparin and ancrod were found to be most effective. These agents were administered to tumour-bearing mice prior to FAA and TNF treatment with little effect on the induced regrowth delay. However: the FAA-induced consumption of platelets in tumour-bearing mice was not blocked by anticoagulant treatment. These data suggest that platelet consumption occurs independently of the normal coagulation pathway, and further that fibrin deposition may not be a major factor in the antitumour action of FAA. While FAA has been shown to be an effective agent against many murine solid tumours, it has been ineffective in the clinic. In view of the similarities in their anti-tumour effects in mice (i.e. greater effect in vivo than in vitro, steep dose response curves, and greater toxicity towards solid tumours in which they cause a decrease in blood flow and rapid haemorrhagic necrosis,) FAA has been compared to the natural cytokine tumour necrosis factor (TNF) (Finlay et al., 1988) . However, the mechanism of antitumour action of both FAA and TNF is still controversial and the reasons for failure in the clinic remain unclear.
TNF is a potent mediator of many cellular responses in vitro. Important among these are local effects on coagulation, such as the induction of tissue factor (thromboplastin) on the surface of endothelial cells (Nawroth & Stern, 1986; Bevilacqua et al., 1986) . In vivo, TNF has also been shown to induce fibrin deposition specifically within fibrosarcomas (Nawroth et al., 1988) . In a similar manner, FAA is able to induce procoagulant activity in endothelial cells in vitro (Murray et al., 1991a) , while in vivo, FAA significantly alters the coagulation properties of plasma in tumour-bearing mice and causes a dose dependent thrombocytopaenia at early times after treatment (Murray et al., 1989) . It has been postulated that local changes in coagulation may be the mechanism by which TNF, and possibly FAA, induce reduction of tumour blood flow, eventually leading to haemorrhagic necrosis (Nawroth et al., 1988; Shimomura et al., 1988; Murray et al., 1989) .
To test the hypothesis that change in coagulation properties are relevant to the action of FAA, we tested several different anticoagulant agents for their effect on the coagulation properties of murine plasma using the clotting time (CT) and the prothrombin time (PT) assays; we found that heparin and ancrod were effective anticoagulants in vivo. These were tested for their effect on the antitumour action of both FAA and TNF, using regrowth delay assay with the CaNT carcinoma. In addition, platelet numbers and coagulation parameters which had been shown to change markedly in tumour-bearing mice following FAA treatment were measured.
Materials and methods

Mice and tumours
Experiments were performed with 12-16 week old male CBA/HtBSVS mice. The tumour used in the study was the CaNT tumour, a moderately differentiated adenocarcinoma passaged in syngeneic mice. Tumours were implanted subcutaneously on the back as described elsewhere Plasma collection and coagulant assays The collection of mouse plasma and the ex vivo coagulation assays and platelet counts have been described previously (Murray et al., 1989) . Anaesthetised mice were injected in- Table I shows a summary of the drugs and doses used in the study, and their mode of action. Heparin and ancrod were found to be most effective at preventing clotting in ex vivo assays, while streptokinase, warfarin, hirudin and urokinase + heparin all had no effect on ex vivo clotting times. At the highest doses testes, heparin produced extensive bleeding at the i.v. injection site, while after ancrod the mice appeared ill for perhaps 4 h before recovering. In general, the mice tolerated the high doses well.
Mice treated with heparin at a dose of 500 U kg showed a significant increase in both clotting time (CT), and prothrombin time (PT); Table I shows the time course of CT and PT for non-tumour bearing mice following intravenous injection of heparin or ancrod. The control values (no treatment) are shown at time 0. For the CT assay, formation of fibrin strands, which marks the completion of the assay, was not observed in murine plasma until at least 120 min after heparin administration. By 360 min, the CT had returned to near control levels. For the PT assay, clot formation was not observed for at least 60 min following heparin injection, and by 360 min clot formation had returned to control values.
Ancrod was also an effective anticoagulant agent in mice. Table II shows CT and PT as a function of time after ancrod administration (5 U kg-'). The effect was more prolonged than that of heparin and the plasma was unable to clot in the CT and PT assays for at least 6 h after ancrod administra- the dose range tested.
The combination of heparin (500 U kg-') plus FAA (300 mg kg-') was administered to mice and the CT and PT determined. As expected, the administration of FAA alone produced a decrease in the clotting time in non-tumour CBA mice within 30 min post-administration (Murray et al., 1989) . However, when given in combination with heparin, the CT response was indistinguishable from mice given heparin alone (data not shown), i.e. no clotting was observed for at least 90 min.
Effects of agents or circulating platelets numbers
The effect of heparin and ancrod on the number of circulating platelets was measured, either alone or in combination with FAA. Shown in Figure la are the platelet numbers for CBA mice bearing CaNT tumour as a function of time following administration of heparin (2 x 500 U kg-'), FAA (200 or 300 mg kg-'), or heparin followed 15 min later by FAA. Heparin alone induced a slight increase in circulating platelet numbers from 1 h to 4 h, and FAA induced a sharp decrease in numbers. The combination of FAA and heparin produced platelet levels identical to FAA alone.
Shown in Figure lb are the platelet numbers following administration of ancrod (5 U kg-'), FAA (200 or 360 mg kg-'), or ancrod followed 30 min later by FAA. Ancrod alone induced a slight decrease in the platelet numbers at 6 h post administration. Again, prior administration of ancrod did not abrogate the FAA-induced reduction in platelets. In non-tumour bearing mice, heparin and ancrod had no effect on the number of circulating platelets either alone or in combination with FAA (data not shown).
Regrowth delay Anticoagulants were administered to mice bearing CaNT tumours of 7-8 mm mean diameter prior to treatment with FAA (200 mg kg-') or TNF (10 pg/mouse), to determine whether the antitumour effect of either agent could be diminished. Heparin was administered 15 min and ancrod 30 min prior to treatment. While both FAA and TNF induced significant growth delay in this tumour (approximately 8 days in each case), heparin did not significantly reduce the growth delay in either case (Figures 2a and b) , nor did heparin alone affect growth of the tumour. Similar observations were made with ancrod ( Figure 2c and d) , which had no effect on FAA-or TNF-induced growth delay: ancrod alone had no effect on tumour growth.
Discussion
Studies on an extensive range of anticoagulants (see Table I) revealed that heparin and ancrod were most effective at inhibiting ex vivo coagulation of mouse plasma. While FAA normally reduces clotting time of mouse plasma, when used in combination with heparin or ancrod, the ex vivo clotting parameters were dominated by the effect of the anticoagulant and in most cases plasma from these mice would not clot for at least several hours aIter FAA aaministration. By this time levels of circulating FAA following a single dose of 200 mg kg-' have decreased to well below therapeutic levels Damia et al., 1988) . In terms of growth delay, however, heparin and ancrod had no effect on the antitumour action of FAA in the CaNT model. In parallel experiments neither anticoagulant abrogated the effects of TNF. This is consistent with a previous report documenting the inability of heparin to counteract the effects of TNF on growth of the Meth A tumour (Watanabe et al., 1988) , although it has also been reported that the anticoagulant dicoumarol does partially block the effects of TNFa (Shimomura et al., 1988) . Our data suggest that fibrin formation via the normal coagulation cascade is not a necessary comb ponent of the tumour response. Yet a significant body of )o evidence indicates that a reduction in tumour blood flow may be a key component of tumour cell killing (Zwi et al., 1989; Hill et al., 1989; Bibby et al., 1989) component of the tumour response, the cause and possible role of FAA-induced platelet consumption is yet to be elucidated.
